Projects per year
Personal profile
Biography
Professor Eric Morand is Head of the School of Clinical Sciences at Monash Health, Monash University's largest clinical school, and a physician-scientist.
He specialises in the study of systemic lupus erythematosus. He is founder of the Monash Lupus Clinic, Australia's largest research-grounded clinic for patients with SLE, a founding member of the Australian Lupus Registry & Biobank, and Chair of the Asia-Pacific Lupus Collaboration. His clinical research focuses on improving endpoints for clinical research in lupus. His lab has studied the biology of glucocorticoids in rheumatic disease and lupus since 1996.
He is a clinical rheumatologist, and Head of the Monash Health Rheumatology Unit, the largest in Australia.
Research interests
Professor Morand is a physician-scientist whose key interests are clinical outcome measurement and biological profiling in SLE, and the actions of glucocorticoid induced proteins on the immune system. Read more at https://www.monash.edu/medicine/scs/researchers/eric-morand .
His group has pioneered the development and validation of treat-to-target outcome measures in SLE, via the Asia-Pacific Lupus Collaboration, which with over 4,000 patients under study is among the largest cohorts of SLE patients ever assembled.
Biomarker studies in SLE are also a major focus, with thousands of samples linked to longitudinal clinical data archived in the Australian Lupus Registry & Biobank, headquartered at Monash.
His lab discovered the role in rheumatic disease of multiple important glucocorticoid-regulated proteins. Most recently his group defined the role of GILZ in RA, Th17 pathways, B cell activation, and lupus, and are working on exploiting its actions to develop a safe glucocorticoid mimic. His lab also works on innate immunity including the actions of the unique pro-inflammatory protein, MIF.
Clinical activities
Professor Morand is Head of Rheumatology, Monash Health. He works in clinics servicing lupus, rheumatoid arthritis, and complex rheumatology cases, and undertakes ward duty inpatient care in the largest service in the country.
Consulting
Advisory expertise and research collaboration experience with international biotech and Pharma companies.
Special interests include Lupus / SLE outcome measures, trials, translational research and biomarkers.
Community service
Professor Morand is a Board member of Rare Voices Australia, has served on the board of the Australian Rheumatology Association and is a member of the Scientific Advisory Board of the ARA Research Trust.
Research area keywords
- Systemic Lupus Erythematosus
- glucocorticoids
- Lupus
- SLE
- RA
- GILZ
- MIF
- Rheumatoid Arthritis
- Rheumatology
- outcome measures
- Clinical Trials
- Translational Research
- Cytokines
Network
-
Biomarker profiles in Indigenous Australians with systemic lupus erythematosus
Eades, L. & Morand, E.
4/03/22 → 31/12/24
Project: Research
-
Achieving benefit without harm: a next-generation glucocorticoid replacement
Jones, S., Morand, E., Nicholson, S. E., Russ, B., Vincent, F., Harris, J., Moore, G., Goldberg, R., Turner, S. & Rosenbluh, S.
1/01/22 → 31/12/25
Project: Research
-
-
Defining NF1 clinical variation at the microscale to discover new therapeutic targets
Ellisdon, A., Halls, M., Schittenhelm, R., Morand, E., Whisstock, J. & Sloan, E.
1/06/21 → 31/05/24
Project: Research
-
-
Cognitive dysfunction in systemic lupus erythematosus: how do we advance our understanding?
Raghunath, S., Glikmann-Johnston, Y., Hanly, J. G., Morand, E. F., Stout, J. C. & Hoi, A., 2022, (Accepted/In press) In: The Lancet Rheumatology. 10 p.Research output: Contribution to journal › Review Article › Research › peer-review
-
Measurement of specific organ domains in lupus randomized controlled trials: a scoping review
Connelly, K., Vettivel, J., Golder, V., Kandane-Rathnayake, R. & Morand, E. F., Apr 2022, In: Rheumatology. 61, 4, p. 1341-1353 13 p.Research output: Contribution to journal › Review Article › Research › peer-review
-
Response to: 'Phsician's global assessment is often useful in SLE, but not always: The case of clinical remission' by Zen et al
Askanase, A., Oon, S., Huq, M., Calderone, A., Morand, E. F., Nikpour, M. & Aranow, C., 1 May 2022, In: Annals of the Rheumatic Diseases. 81, 5, 1 p., e78.Research output: Contribution to journal › Letter › Other › peer-review
Open Access -
Algorithm for calculating high disease activity in SLE
Hoi, A., Nim, H. T., Koelmeyer, R., Sun, Y., Kao, A., Gunther, O. & Morand, E., Sep 2021, In: Rheumatology. 60, 9, p. 4291-4297 7 p.Research output: Contribution to journal › Article › Research › peer-review
2 Citations (Scopus) -
Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus
Furie, R., Morand, E. F., Askanase, A. D., Vital, E. M., Merrill, J. T., Kalyani, R. N., Abreu, G., Pineda, L. & Tummala, R., 1 Jul 2021, In: Lupus. 30, 8, p. 1254–1263 10 p.Research output: Contribution to journal › Article › Research › peer-review
6 Citations (Scopus)
Prizes
-
Dean's Award for Research (Enterprise)
Morand, Eric (Recipient), 1 Aug 2018
Prize: Prize (including medals and awards)
-
Distinguished Innovator Award, Lupus Research Alliance
Morand, Eric (Recipient), 2015
Prize: National/international honour
-
-
-
Monash University Honour Roll
Morand, Eric (Recipient), 1 Dec 2021
Prize: Prize (including medals and awards)
Activities
- 2 Editorial responsibility
-
The Lancet Rheumatology (Journal)
Eric Morand (Editorial board member)
1 Jan 2020 → …Activity: Publication peer-review and editorial work types › Editorial responsibility
-
Nature Reviews Rheumatology (Journal)
Eric Morand (Editorial board member)
2014Activity: Publication peer-review and editorial work types › Editorial responsibility